Slide 1: Fate can be altered
Fate can be altered October 2, 2025
Slide 2: Presenting Team
Presenting Team Marcin Szumowski Zbigniew Zasłona Chairman of the Board & CEO Chief Scientific Officer Piotr Iwanowski Monika Czarnecka Chief Medical Officer Finance Director 10/2/2025 2
Slide 3: Summary | Molecure on the path of continued growth
Summary | Molecure on the path of continued growth OATD-01 (in Phase 2 clinical development) OATD-02 (in Phase 1 clinical development) o Accelerating patient o Escalating the dose towards MTD: enrolment in the KITE study a more dynamic dose escalation, o With potential expansion currently at 40 mg/d
Slide 4: Molecure | Current pipeline
Molecure | Current pipeline CSR* 10/2/2025 4 *Clinical Study Report
Slide 5: OATD-01: Phase 2 clinical study in pulmonary sarcoidosis
OATD-01: Phase 2 clinical study in pulmonary sarcoidosis 10/2/2025 5
Slide 6: OATD-01 | Phase 2 PoC in sarcoidosis (KITE study)
OATD-01 | Phase 2 PoC in sarcoidosis (KITE study) A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study) C
Slide 7: OATD-01 | KITE study: Footprint & progress
OATD-01 | KITE study: Footprint & progress FDA and MHRA Change in study Netherlands First Interim LPLV H1 2027 FPFV (UK) EU approval FPFV (US/EU) approval & sites analysis Results approvals protocol (planned) activation (planned) and CSR Jul-Nov Mar 2024 May 2024 Q4 2024 May 2025 Aug-Sep Q1 2026 H2
Slide 8: OATD-01 | KITE: Boosting patient enrolment
OATD-01 | KITE: Boosting patient enrolment Study protocol amendment Study awareness & recognition Modifications of in/ex criteria to ease patient Dec 2024 & Jul 2025: national pulmonology recruitment & study procedures: now fully conferences (Greece); Mar 2025: WASOG Task implemented in all countrie
Slide 9: Genomic data mining: Causal effect of CHIT1 level
Genomic data mining: Causal effect of CHIT1 level Effect of chitinase 1 levels expression on sarcoidosis MR – Rücker method 0.0745±0.0354, p=0.0355 Using Mendelian randomization (MR), the estimated effect of chitotriosidase levels on sarcoidosis is positive (estimate = 0.0745 +- 0.0354, p=0.0355), m
Slide 10: PET/CT and CHIT1 in pulmonary sarcoidosis: New data from medical literature
PET/CT and CHIT1 in pulmonary sarcoidosis: New data from medical literature 1355 studies were screened and 17 (n = 708 patients) found suitable for 90 patients with sarcoidosis studied: 63 were treated (50 with corticosteroids); all assessment of the diagnostic performance or prognostic value of PET
Slide 11: OATD-01 | MASH remains an attractive indication for Big Pharma
OATD-01 | MASH remains an attractive indication for Big Pharma Key Players: MASH: A Growing Health Challenge • ~32% of adults globally (~45% in North America) have metabolic dysfunction-associated steatotic liver disease (MASLD) and are at risk of MASH • The global prevalence of MASH, the more aggre
Slide 12: OATD-02: A first in class dual arginase inhibitor for cancer indications
OATD-02: A first in class dual arginase inhibitor for cancer indications 10/2/2025 12
Slide 13: OATD-02 | Phase 1 clinical study overview
OATD-02 | Phase 1 clinical study overview Patient population: Relapsed/refractory advanced and/or metastatic solid tumors Design: First-In-Human (FIH) OATD-02 Colorectal cancer, platinum-resistant serous Open-label single-arm dose-escalation ovarian cancer, pancreatic ductal cancer, renal monotherap
Slide 14: OATD-02 | First-in-Human study: Executing the more dynamic dose escalation
OATD-02 | First-in-Human study: Executing the more dynamic dose escalation 6th dose level group Min. 3 patients o After each dose level completed, the decision on 5th dose level group next step is taken by Sponsor under Min. 3 patients 80 recommendation by Safety Review Committee mg/day 4th dose lev
Slide 15: Reduced & focused pre-clinical pipeline
Reduced & focused pre-clinical pipeline 10/2/2025 15
Slide 16: Preclinical programs
Preclinical programs Protein targets mRNA targets o USP21 – active and selective lead o X target – early program at the stage of compound discovered, patent application hit-to-lead, inducer of apoptosis for pending, in vivo PoC planned cancer indication, screening cascade established, active compoun
Slide 17: moleRNA platform services
moleRNA platform services an innovative platform for designing small molecules targeting RNA with advanced in silico and wet lab methods, starting from the RNA sequence Thanks to team’s know-how and proven solutions, we are able to effectively support business partners (biotechs and academic groups)
Slide 18: Finance
Finance 10/2/2025 18
Slide 19: Financial results
Financial results Consolidated Statement of Profit or Loss kPLN H1 2025 H1 2024 Revenue 3 603 348 Costs 12 908 15 600 R&D and Business Development 7 258 11 074 General and administration 5 650 4 526 EBIT - 9 305 - 15 253 92 Employees Net Financial Income 610 687 Net loss - 8 694 - 14 566 71 by 30.09
Slide 20: Changes in cash
Changes in cash 60 m PLN 2,5 50 30,3 40 -8,7 0,8 32,5 30 -8,2 -2,3 20 18,2 10 0 Cash at BoP Share issue Grants Loss for H1 Clinical stage Working capital Other inflows Cash at EoP R&D 10/2/2025 20
Slide 21: R&D expenses
R&D expenses Clinical stage Early stage 7 M PLN 6 5 4 3 2 1 - Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 10/2/2025 21
Slide 22: Budget and financing
Budget and financing Molecure intends to use four possible sources of financing its activites: transaction revenues such as up-front payment(s) from one or more licensing agreements, grants and subsidies, share issue (SPO) and/or debt instruments. R&D and G&A expenses ~90 m PLN Financing of Molecure
Slide 23: Grants
Grants Eligible costs Funding Project submission Filing Status Decision Institution [m PLN] [m PLN] Agreement mRNA 52 33 05.23 signed in 2023 Granted on New service with AI tool* 47 27** 03.25 26.09 Expected Q4 USP7 12 7 06.25 2025 Expected Q4 US Dept. undisclosed target 6 6 06.25 of Defence 2025 Ex
Slide 24: Business Development and plans
Business Development and plans 10/2/2025 24
Slide 25: BD activities
BD activities Notes: 60+ one-on-one o Continued active engagement with a diverse set of potential pharma & biotech partners, meetings in KOLs (Key Opinion Leaders), and industry stakeholders to expand Molecure’s strategic network. H1 2025 o Ongoing evaluation and pursuit of new out-licensing and co-
Slide 26: Molecure | Key milestones 2025/2026
Molecure | Key milestones 2025/2026 OATD-01 o PoC study (KITE) in pulmonary sarcoidosis: Interim data analysis by the independent OATD-02 (unblinded) Data Monitoring Committee after completion of dosing of 30 patients o Establishing the therapeutic dose (RP2D) (Q1 2026), to be followed by sharing (p
Slide 27: Q&A
Q&A 10/2/2025 27
Slide 28: Disclaimer
Molecure SA (”MOC") and its Board and employees make no warranties or assurances regarding the accuracy or completeness of any representations or other materials contained herein. The information and data contained herein reflect the current conditions and assessments of the market situation as at t